Syngene to Triple Biologics Capacity by H2 with Upgraded Stelis Unit

Syngene International, a subsidiary of Biocon, is poised to significantly enhance its production capacity following the acquisition of Unit 3, a biologics manufacturing facility, from Stelis Biopharma. According to a senior company official, this move is anticipated to increase production capacity by 250 percent. Originally designed for vaccine production, Unit 3 is undergoing repurposing to focus on manufacturing monoclonal antibodies.

The acquisition of the multi-modal biologics manufacturing facility was finalized on July 4, 2023, for Rs 702 crore, with the deal concluded by December 2023.

"Initially established as a vaccine production facility, meticulous adaptations have been made over the past five to six months to align with the stringent requirements for antibody production," stated the official.

BS